Artemisinin-based combination therapy for ... - The Cochrane Library

More documents

Recommendations

Info

$Interventions for treating proximal humeral fractures in adults (Review)$

des derives de l’artemisinine dans le traitement de l’acces palustre non-complique au Burundi]. Tropical Medicine and International Health 2004; Vol. 9, issue 6:673–9. Ndiaye 2005 {published data only} Ndiaye P, Faye B, Ndiaye J, Ndiaye D, Diallo I, Seck P, et al.Efficacite et tolerance de l’association Artesunate plus Amodiaquine (Amonate®) versus Arthemether plus lumefantrine (Coartem®) six doses dans le traitement des acces palustres simples a Plasmodium falciparum au Senegal. Acta Tropica 2005;95 Suppl 1 [Abstracts from the 4th MIM Pan-African Conference]:254–5. Obonyo 2007 {published data only} Obonyo CO, Juma EA, Ogutu BR, Vulule JM, Lau J. Amodiaquine combined with sulfadoxine/pyrimethamine versus artemisininbased combinations for the treatment of uncomplicated falciparum malaria in Africa: a meta-analysis. Transactions of the Royal Society of Tropical Medicine and Hygiene 2007;101(2):117–26. Okell 2008 {published data only} Okell LC, Drakeley CJ, Ghani AC, Bousema T, Sutherland CJ. Reduction of transmission from malaria patients by artemisinin combination therapies: A pooled analysis of six randomized trials. Malaria Journal 2008;7:125. Piola 2005 {published data only} Piola P, Fogg C, Bajunirwe F, Biraro S, Grandesso F, Ruzagira E, et al.Supervised versus unsupervised intake of six-dose artemetherlumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial. Lancet 2005; Vol. 365, issue 9469:1467–73. Rwagacondo 2003 {published data only} Rwagacondo CE, Niyitegeka F, Sarushi J, Karema C, Mugisha V, Dujardin JC, et al.Efficacy of amodiaquine alone and combined with sulfadoxine-pyrimethamine and of sulfadoxine pyrimethamine combined with artesunate. American Journal of Tropical Medicine and Hygiene 2003; Vol. 68, issue 6:743–7. Sagara 2006 {published data only} Sagara I, Dicko A, Djimde A, Guindo O, Kone M, Tolo Y, et al.A randomized trial of artesunate-sulfamethoxypyrazinepyrimethamine versus artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Mali. American Journal of Tropical Medicine and Hygiene 2006; Vol. 75:630–636. Sowunmi 2007a {published data only} Sowunmi A, Gbotosho GO, Adedeji AA, Tambo E, Fateye BA, Happi CT, et al.The effects of artemether-lumefantrine vs amodiaquine-sulfalene-pyrimethamine on the hepatomegaly associated with Plasmodium falciparum malaria in children. Parasitology Research 2007; Vol. 100, issue 3:511–7. Sowunmi 2007b {published data only} Sowunmi A, Gbotosho GO, Happi CT, Adedeji AA, Fehintola FA, Folarin OA, et al.Therapeutic efficacy and effects of artemetherlumefantrine and amodiaquine-sulfalene-pyrimethamine on gametocyte carriage in children with uncomplicated Plasmodium falciparum malaria in Southwestern Nigeria. American Journal of Tropical Medicine and Hygiene 2007; Vol. 77, issue 2:235–41. Tall 2005 {published data only} Tall A, Rabarijaona L, Bedja S, Rahamatou S, Ahmed O, Ratsimbasoa A, et al.Efficacy of artesunate + amodiaquine, Artemisinin-based combination therapy for treating uncomplicated malaria (Review) Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. artesunate + sulfadoxine-pyrimethamine, chloroquine + sulfadoxine-pyrimethamine in P.falciparum malaria in Comoros. Acta Tropica 2005;95 Suppl 1 [Abstracts from the 4th MIM Pan- African Conference]:223–4. Tall 2007 {published data only} Tall A, Rabarijaona LP, Robert V, Bedja SA, Ariey F, Randrianarivelojosia M. Efficacy of artesunate plus amodiaquine, artesunate plus sulfadoxine-pyrimethamine, and chloroquine plus sulfadoxine-pyrimethamine in patients with uncomplicated Plasmodium falciparum in the Comoros Union. Acta Tropica 2007. Thapa 2007 {published data only} Thapa S, Hollander J, Linehan M, Cox-Singh J, Bista MB, Thakur GD, et al.Comparison of artemether-lumefantrine with sulfadoxine-pyrimethamine for the treatment of uncomplicated Falciparum malaria in Eastern Nepal. American Journal of Tropical Medicine and Hygiene 2007; Vol. 77, issue 3:423–30. Tranh 2009 {published data only} Thanh NX, Trung TN, Phong NC, Thien NX, Dai B, Dennis Shanks G, et al.Open label randomized comparison of dihydroartemisinin-piperaquine and artesunate-amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in central Vietnam. Tropical Medicine and International Health 2009; 14(5):1–8. van den Broek 2005b {published data only} van den Broek I, Amsalu R, Balasegaram M, Hepple P, Alemu E, Hussein el B, et al.Efficacy of two artemisinin combination therapies for uncomplicated falciparum malaria in children under 5 years, Malakal, Upper Nile, Sudan. Malaria Journal 2005; Vol. 4, issue 1:14. van Vugt 1998 {published data only} van Vugt M, Brockman A, Gemperli B, Luxemburger C, Gathmann I, Royce C, et al.Randomized comparison of artemether-benflumetol and artesunate-mefloquine in treatment of multidrug-resistant falciparum malaria. Antimicrobial Agents Chemotherapy 1998; Vol. 42, issue 1:135–9. Vugt 1999 {published data only} Vugt MV, Wilairatana P, Gemperli B, Gathmann I, Phaipun L, Brockman A, et al.Efficacy of six doses of artemether-lumefantrine (benflumetol) in multidrug-resistant Plasmodium falciparum malaria. American Journal of Tropical Medicine and Hygiene 1999; Vol. 60, issue 6:936–42. Wilairatana 2002 {published data only} Wilairatana P, Krudsood S, Chalermrut K, Pengruksa C, Srivilairit S, Silachamroon U, et al.An open randomized clinical trial of Artecom vs artesunate-mefloquine in the treatment of acute uncomplicated falciparum malaria in Thailand. Southeast Asian Journal of Tropical Medicine and Public Health 2002; Vol. 33, issue 3:519–24. Wiseman 2006 {published data only} Wiseman V, Kim M, Mutabingwa TK, Whitty CJ. Costeffectiveness study of three antimalarial drug combinations in Tanzania. PLoS Medicine 2006; Vol. 3, issue 10. Additional references 34
Adjuik 2004 Adjuik M, Babiker A, Garner P, Olliaro P, Taylor W, White N, International Artemisinin Study Group. Artesunate combinations for treatment of malaria: meta-analysis. The Lancet 2004;363 (9402):9–17. Agomo 2008 Agomo PU, Meremikwu MM, Watila IM, Omalu IJ, Odey FA, Oguche S, et al.Efficacy, safety and tolerability of artesunatemefloquine in the treatment of uncomplicated Plasmodium falciparum malaria in four geographic zones of Nigeria. Malaria Journal 2008;7:172. Bukirwa 2005 Bukirwa H, Orton L. Artesunate plus mefloquine versus mefloquine for treating uncomplicated malaria. Cochrane Database of Systematic Reviews 2005, Issue 4. [DOI: DOI: 10.1002/ 14651858.CD004531.pub2] Bukirwa 2006 Bukirwa H, Critchley J. Sulfadoxine-pyrimethamine plus artesunate versus sulfadoxine-pyrimethamine plus amodiaquine for treating uncomplicated malaria. Cochrane Database of Systematic Reviews 2006, Issue 1. [DOI: 10.1002/14651858.CD004966.pub2] Cattamanchi 2003 Cattamanchi A, Kyabayinze D, Hubbard A, Rosenthal PJ, Dorsey G. Distinguishing recrudescence from reinfection in a longitudinal antimalarial drug efficacy study: comparison of results based on genotyping of msp-1, msp-2, and glurp. American Journal of Tropical Medicine and Hygiene 2003;68(2):133–9. Guyatt 2008 Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schünemann HJ. GRADE Working Group.Rating quality of evidence and strength of recommendations: What is “quality of evidence” and why is it important to clinicians?. BMJ 2008;336 (7651):995–8. Higgins 2008 Higgins JPT, Altman DG (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors), Cochrane Handbook of Systematic Reviews of Intervention. Version 5.0.0 (updated February 2008). The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org. Chichester: John Wiley & Sons Ltd. Lefebvre 2008 Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008). The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org. Massougbodji 2002 Massousgbodji A, Kone Kinde Gazard D, same-Ekobo A, Cambon N, Mueller EA. A randomized double-blind study on the efficacy and safety of a practical three-day regimen with artesunate and mefloquine for the treatment of uncomplicated Plasmodium falciparum malaria in Africa. Transactions of the Royal Society of Tropical Medicine and Hygiene 2002;96(6):655–659. Artemisinin-based combination therapy for treating uncomplicated malaria (Review) Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. Mayxay 2004 Mayxay M, Pukrittayakamee S, Newton PN, White NJ. Mixedspecies malaria infections in humans. Trends in Parasitology 2004; 20(5):233–40. McIntosh 1999 McIntosh HM, Olliaro P. Artemisinin derivatives for treating uncomplicated malaria. Cochrane Database of Systematic Reviews 1999, Issue 2. [DOI: 10.1002/14651858.CD000256] Meshnick 1996 Meshnick SR, Taylor TE, Kamchonwongpaisan S. Artemisinin and the antimalarial endoperoxides: from herbal remedy to targeted chemotherapy. Microbiological Reviews 1996;60(2):301–15. Newton 2002 Newton PN, van Vugt M, Teja-Isavadharm P, Siriyanonda D, Rasameesoroj M, Teerapong P, et al.Comparison of oral artesunate and dihydroartemisinin antimalarial bioavailabilities in acute Falciparum malaria. Antimicrobial Agents Chemotherapy 2002;46 (4):1125–7. Nosten 2007 Nosten F, White NJ. Artemisinin-based combination treatment of falciparum malaria. American Journal of Tropical Medicine and Hygiene 2007;77 (6 Suppl):181–92. Omari 2005 Omari AAA, Gamble C, Garner P. Artemether-lumefantrine (sixdose regimen) for treating uncomplicated falciparum malaria. Cochrane Database of Systematic Reviews 2005, Issue 4. [DOI: 10.1002/14651858.CD005564] Omari 2006 Omari AAA, Gamble C, Garner P. Artemether-lumefantrine (fourdose regimen) for treating uncomplicated falciparum malaria. Cochrane Database of Systematic Reviews 2006, Issue 2. [DOI: 10.1002/14651858.CD005965] Price 1996 Price RN, Nosten F, Luxemburger C, ter Kuile FO, Paiphun L, Chongsuphajaisiddhi T, et al.Effects of artemisinin derivatives on malaria transmissibility. The Lancet 1996;347(9016):1654–8. Price 1999 Price R, van Vugt M, Phaipun L, Luxemburger C, Simpson J, McGready R, et al.Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives. American Journal of Tropical Medicine and Hygiene 1999;60(4):547–55. Pukrittayakamee 2000 Pukrittayakamee S, Chantra A, Simpson JA, Vanijanonta S, Clemens R, Looareesuwan S, et al.Therapeutic responses to different antimalarial drugs in vivax malaria. Antimicrobial Agents and Chemotherapy 2000;44(6):1680–5. Qinghaosu 1979 Qinghaosu Antimalarial Coordinating Research Group. Antimalarial studies on qinghaosu. Chinese Medical Journal 1979; 92:811–6. Review Manager 5 The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008. 35
Page 1 and 2: Artemisinin-based combination thera
Page 3 and 4: Analysis 2.2. Comparison 2 Dihydroa
Page 5 and 6: Analysis 10.5. Comparison 10 Arteme
Page 7 and 8: [Intervention Review] Artemisinin-b
Page 9 and 10: B A C K G R O U N D Malaria is a di
Page 11 and 12: drugs and the treatment comparisons
Page 13 and 14: this analysis into participants who
Page 15 and 16: Figure 1. Methodological quality su
Page 17 and 18: confidence intervals of the estimat
Page 19 and 20: Anaemia Hasugian 2005 IDN found tha
Page 21 and 22: Three trials report significantly m
Page 23 and 24: or those treated for P. vivax at ba
Page 25 and 26: Early vomiting Not reported. D I S
Page 27 and 28: Figure 4. Olliaro-Vaillant plot. Da
Page 33 and 34: Figure 10. Olliaro-Vaillant plot. D
Page 35 and 36: of findings tables’. For these ta
Page 37 and 38: Huambo and Bie provinces, central A
Page 39: References to studies excluded from
Page 43 and 44: C H A R A C T E R I S T I C S O F S
Page 45 and 46: Ashley 2003a THA (Continued) Outcom
Page 47 and 48: Ashley 2003b THA (Continued) Alloca
Page 49 and 50: Ashley 2005 THA (Continued) Exclusi
Page 51 and 52: Bonnet 2004 GIN (Continued) Item Au
Page 53 and 54: Bukirwa 2005 UGA Methods Trial desi
Page 55 and 56: Djimde 2004 MLI (Continued) • AS
Page 57 and 58: Dorsey 2006 UGA (Continued) Item Au
Page 59 and 60: Fanello 2004 RWA Methods Trial desi
Page 61 and 62: Faye 2003 SEN (Continued) Outcomes
Page 63 and 64: Grande 2005 PER (Continued) Allocat
Page 65 and 66: Guthmann 2004 AGO (Continued) All d
Page 67 and 68: Hasugian 2005 IDN Methods Trial des
Page 69 and 70: Hutagalung 2002 THA (Continued) 5.
Page 71 and 72: Janssens 2003 KHM (Continued) Free
Page 73 and 74: Karema 2004 RWA (Continued) Interve
Page 75 and 76: Karunajeewa 2007 PNG (Continued) Ri
Page 77 and 78: Kobbe 2007 GHA (Continued) Exclusio
Page 79 and 80: Koram 2003 GHA (Continued) Adequate
Page 81 and 82: Martensson 2003 TZA Methods Trial d
Page 83 and 84: Mayxay 2003 LAO (Continued) 1. Feve
Page 85 and 86: Menard 2006 MDG Methods Trial desig
Page 87 and 88: Mens 2007 KEN (Continued) Risk of b
Page 89 and 90: Mutabingwa 2004 TZA (Continued) •
Page 91 and 92:
Owusu-Agyei 2006 GHA (Continued) Fr
Page 93 and 94:
Sagara 2005b MLI (Continued) • 25
Page 95 and 96:
Smithuis 2004 MMR (Continued) Risk
Page 97 and 98:
Stohrer 2003 LAO Methods Trial desi
Page 99 and 100:
Swarthout 2004 ZAR (Continued) Note
Page 101 and 102:
Tran 2002 VNM Methods Trial design:
Page 103 and 104:
Van den Broek 2003a BGD (Continued)
Page 105 and 106:
Van Vugt 1998 THA Methods Trial des
Page 107 and 108:
Yeka 2004 UGA (Continued) Risk of b
Page 109 and 110:
Yeka 2007 UGA (Continued) Free of o
Page 111 and 112:
Zongo 2007 BFA (Continued) Novartis
Page 113 and 114:
(Continued) Fofana 2005 Conference
Page 115 and 116:
D A T A A N D A N A L Y S E S Compa
Page 117 and 118:
2.2 Asia 1 317 Risk Ratio (M-H, Fix
Page 119 and 120:
Comparison 5. Dihydroartemisinin-pi
Page 121 and 122:
Comparison 8. Artesunate plus meflo
Page 123 and 124:
Comparison 10. Artemether-lumefantr
Page 125 and 126:
Comparison 12. Artesunate plus amod
Page 127 and 128:
5.2 DHA-P 3 doses 3 1116 Risk Ratio
Page 129 and 130:
Comparison 21. How does Artesunate
Page 131 and 132:
Analysis 1.3. Comparison 1 Dihydroa
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
(... Continued) Study or subgroup D
Page 139 and 140:
Analysis 1.12. Comparison 1 Dihydro
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Page 157 and 158:
Page 159 and 160:
Page 161 and 162:
Page 163 and 164:
(... Continued) Study or subgroup A
Page 165 and 166:
Analysis 6.6. Comparison 6 Artesuna
Page 167 and 168:
Page 169 and 170:
Page 171 and 172:
Page 173 and 174:
Analysis 9.2. Comparison 9 Artemeth
Page 175 and 176:
Page 177 and 178:
Analysis 9.8. Comparison 9 Artemeth
Page 179 and 180:
Page 181 and 182:
Page 183 and 184:
Analysis 10.2. Comparison 10 Arteme
Page 185 and 186:
Page 187 and 188:
Page 189 and 190:
Page 191 and 192:
Page 193 and 194:
Page 195 and 196:
Page 197 and 198:
Analysis 12.2. Comparison 12 Artesu
Page 199 and 200:
Page 201 and 202:
Page 203 and 204:
Page 205 and 206:
Page 207 and 208:
Analysis 14.2. Comparison 14 Dihydr
Page 209 and 210:
Page 211 and 212:
Page 213 and 214:
Page 215 and 216:
Page 217 and 218:
Page 219 and 220:
Analysis 20.1. Comparison 20 How do
Page 221 and 222:
Analysis 21.1. Comparison 21 How do
Page 223 and 224:
(Continued) 2. How does artesunate
Page 225 and 226:
(Continued) Sensitivity analysis 1
Page 227 and 228:
(Continued) Smithuis 2004 MMR (652
Page 229 and 230:
Dihydroartemisinin-piperaquine vs A
Page 231 and 232:
(Continued) Mayxay 2003 LAO (220 pa
Page 233 and 234:
Artesunate plus mefloquine vs Amodi
Page 235 and 236:
(Continued) Faye 2003 SEN (509 part
Page 237 and 238:
Artemether-lumefantrine vs Artesuna
Page 239 and 240:
(Continued) Zongo 2005 BFA (521 par
Page 241 and 242:
(Continued) Faye 2003 SEN (521 part
Page 243 and 244:
PCR = polymerase chain reaction PCV
Page 245 and 246:
(Continued) Proportion with anaemia
Page 247 and 248:
(Continued) Vivax efficacy: P. viva
Page 249 and 250:
(Continued) Efficacy: Total Failure
Page 251 and 252:
(Continued) Outcomes Illustrative c
Page 253 and 254:
Page 255 and 256:
(Continued) GRADE Working Group gra
Page 257 and 258:
Footnotes 1 Data were also availabl
Page 259 and 260:
8 Very serious imprecision: There w
Page 261 and 262:
Page 263 and 264:
(Continued) justed Vivax efficacy:
Page 265 and 266:
(Continued) Harms: Serious adverse
Page 267 and 268:
(Continued) Harms: Early vomiting -
Page 269 and 270:
1 Dorsey 2006 UGA; Faye 2003 SEN; K
show all

Artemisinin-based combination therapy for ... - The Cochrane Library

Create successful ePaper yourself

Delete template?

Save as template?